# Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer

> **NCT00614978** · PHASE1 · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Brain Metastases
- HER2 Positive

## Interventions

- **DRUG:** lapatinib and temozolomide

## Key facts

- **NCT ID:** NCT00614978
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614978, "Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00614978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*